Gene Expression Research

The latest news about RNA-seq, gene expression profiling, and transcriptome sequencing.

The company expects to be able to offer at least one test commercially by the end of this year or early next, with research now starting on two others.

The company saw total revenues of $27 million and product revenues of $16.9 million, as it had estimated in preliminary earnings report last month.

NanoString Technologies this week provided investors with a mixed bag of news as it released its second quarter earnings and financial outlook for the rest of the year.

Ascendas will develop and commercialize molecular diagnostic systems and assays using certain of Fluidigm's microfluidic technologies.

New data now suggests that evaluating PD-L2 levels might better predict response to PD-1 targeting immune-oncology drugs than current tests that only measure PD-L1.